Abstract Library

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3745 Prediction of disease recurrence in patients after complete PanNET G2 resection

Introduction: The number of pancreatic neuroendocrine tumors (PanNETs) detected has been increasing over the past decade. Surgical resection is the only potentially curative treatment for PanNETs, but the risk factors for recurrence are not fully understood, which is of clinical value especially for G2 PanNETs due to their high heterogeneity.

Conference:

Presenting Author:

Authors: Opalinska M, Olearska H, Sowa-Staszczak A, Morawiec-Sławek K, Kurzyńska A,

Keywords: PanNET G2, recurrence risk, NET G2, surgery, PanNET,

#3623 Characteristics of clinical features of MEN1-associated and sporadic insulinomas – One clinical center experience

Introduction: Insulinomas are usually small, benign tumors that can be radically treated surgically. They may occur as sporadic or be associated with hereditary syndromes, (mainly MEN1 syndrome). In such cases, they may differ in clinical presentation including risk of recurrence and dissemination after curative surgery, which translates into long-term therapy effects.

Conference:

Presenting Author:

Authors: Opalinska M, Gilis-Januszewska A, Morawiec-Sławek K, Kurzyńska A, Sowa-Staszczak A,

Keywords: MEN1, insulinoma, sporadic insulinoma, MEN1 insulinoma,

#3376 Usefulness of corrected SUV max change in metastatic NET lesions (before and after PRRT) obtained by [68Ga]Ga-DOTA-TATE PET/CT as a prognostic factor

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option for metastatic neuroendocrine tumor (NET)therapy. The high heterogeneity of the somatostatin receptors (SSTR) density in different NET metastatic lesions and inside single tumors probably influence an clinical outcome. Some studies suggest the response to PRRT assessed on the basis of imaging of SSTR may have a predictive value.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kania-Kuc A, Al Maraih I, Hubalewska-Dydejczyk A,

Keywords: PRRT, NET, outcome, 68Ga-DOTATATE PET/CT, SSTR expression,

#3375 Neuroendocrine tumors associated with ovarian teratoma – One centre experience

Introduction: Ovarian teratomas are frequent gynaecological finding in contrary to ovarian NETs which comprise only 0.1% of all ovarian neoplasms. In contrast to other gynaecological organs like cervix, endometrium vagina or vulva in which the common type of NENs is NECs, in case of ovarian carcinoid the prognosis remains good.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Sowa-Staszczak A, Olearskaa H, Ulatowska-Bialas M, Gilis-Januszewska A,

Keywords: ovarian carcinoid, NET, teratoma, outcome,